Portal de Periódicos da CAPES

Anti-VEGF Therapy and the Retina: An Update

2015; Hindawi Publishing Corporation; Volume: 2015; Linguagem: Inglês

10.1155/2015/627674

2090-0058

Vikas Tah, Harry O. Orlans, Jonathan N. Hyer, Edward J. Casswell, Nizar Din, Vishnu Sri Shanmuganathan, Louise Ramskold, Saruban Pasu,

Retinal and Optic Conditions

Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.